Skip to main content

Table 7 Change in clinical secondary outcome on the FAS population (LOCF approach)

From: Reduction of the Serum Levels of a Specific Biomarker of Cartilage Degradation (Coll2-1) by Hyaluronic Acid (KARTILAGE® CROSS) Compared to Placebo in Painful Knee Osteoarthritis Patients: the EPIKART Study, a Pilot Prospective Comparative Randomized Double Blind Trial

   D-10 D30 D90 D180 Test
LI Treatment group (N = 40) 12.5 ± 3.8 8.3 ± 4.1 8.2 ± 4.3 6.8 ± 4.9 ANOVA
Placebo group (N = 41) 12.5 ± 3.4 9.0 ± 5.0 8.9 ± 5.5 8.1 ± 5.5
  P value 0.9500 0.4983 0.5466 0.3395  
Change in pain (VAS) Treatment group (N = 40) 65.7 ± 11.6 35.9 ± 21.5 31.4 ± 24.2 27.9 ± 23.2 ANOVA
Placebo group (N = 41) 66.4 ± 9.8 38.6 ± 21.6 36.2 ± 25.6 30.8 ± 23.9
  P value 0.7719 0.5659 0.3939 0.5738  
Change in pain intensity adjusted to basal value (VAS) Treatment group (N = 40) −30.1 ± 3.4 −34.8 ± 3.9 −38.2 ± 3.7 ANOVA
Placebo group (N = 41) −27.5 ± 3.4 −29.7 ± 3.8 −35.2 ± 3.7
  P value 0.5925 0.3543 0.5576  
Change in pain intensity responder 30% (VAS) Treatment group (N = 40) 60.0% 70.0% 72.5% Chi-square test
Placebo group (N = 41) 61.0% 65.9% 75.6%
  P value 0.9284 0.6894 0.7495  
Change in pain intensity responder 50% (VAS) Treatment group (N = 40) 50.0% 50.0% 57.5% Chi-square test
Placebo group (N = 41) 43.9% 43.9% 63.4%
  P value 0.5825 0.5825 0.5862  
%OMERACT -OARSI responders/non-responders Treatment group (N = 40) 70.0% 70.0% 67.5% Chi-square test
Placebo group (N = 41) 70.7% 65.9% 61.0%
  P value 0.9425 0.1597 0.3750  
Patient global assessment on disease activity Treatment group (N = 40) 6.6 ± 1.3 3.6 ± 1.9 3.4 ± 2.5 2.9 ± 2.1 ANOVA
Placebo group (N = 41) 6.4 ± 1.3 4.0 ± 2.1 4.1 ± 2.5 3.5 ± 2.4
  P value 0.6411 0.447 0.2052 0.2444